• Explore /
  • Poster
  • / Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.

Rezvilutamide in combination with androgen-deprivation therapy, with or without salvage radiotherapy, for patients experiencing biochemical recurrence following radical prostatectomy: A multi-center, open-label, two-cohort study.

Abstract Poster

Authors

null

Shun Zhang

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

Shun Zhang , Linfeng Xu , Xuefeng Qiu , Junlong Zhuang , Qing Zou , Junqi Wang , Hongqian Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05753566

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS355)

DOI

10.1200/JCO.2024.42.4_suppl.TPS355

Abstract #

TPS355

Poster Bd #

R7

Abstract Disclosures

Similar Posters

First Author: Markus Grabbert

First Author: Edwin Melencio Posadas

First Author: Emerson Lee

First Author: Alan Dal Pra